Start Time: 08:30 January 1, 0000 9:13 AM ET
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Q3 2022 Earnings Conference Call
November 02, 2022, 08:30 AM ET
Company Participants
Nancy Lurker - President and CEO
George Elston - CFO
Jay Duker - COO
Scott Jones - Chief Commercial Officer
Conference Call Participants
Jennifer Kim - Cantor Fitzgerald
Georgi Yordanov - Cowen
Yi Chen - H.C. Wainwright
Yale Jen - Laidlaw & Company
Daniil Gatualin - Chardan
Yuan Zhi - B. Riley
Operator
Welcome to the EyePoint Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. As a reminder, today's conference call is being recorded.
I would now like to turn the conference over to your host, Mr. George Elston, Chief Financial Officer of EyePoint Pharmaceuticals. Please go ahead, sir.
George Elston
Thank you and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals third quarter 2022 financial results and recent corporate developments. With me today are Nancy Lurker, President and Chief Executive Officer; Dr. Jay Duker, Chief Operating Officer; and Scott Jones, Chief Commercial Officer.
Nancy will begin with a review recent corporate updates. Dr. Duker will then discuss Phase 2 clinical trials for EYP-1901. And Scott will comment on our third quarter 2022 commercial performance. I will close with commentary on the third quarter 2022 financial results, and we will then open up the call for your questions.
Earlier this morning, we issued a press release detailing our financial results as well as commercial and operational developments. A copy of this release can be found on the Investor Relations tab on the corporate Web site, www.eyepointpharma.com.
Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. These include statements about our future expectations, clinical developments, and regulatory matters and timelines, the potential success of our products and product candidates, financial projections, and other plans and prospects. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC, and in other filings that we may make with the SEC in the future. Any forward-looking statements represent our views as of today only. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.